{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-115296","form_type":"8-K","ticker":"TBPH","cik":"0001583107","company_name":"Theravance Biopharma, Inc.","filed_at":"2023-11-07T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.638903+00:00","generated_at":"2026-06-08T15:21:30.091058+00:00","sec_items":["2.02","9.01","5.02"],"event_type":"earnings","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Q3 loss narrows to $9.0M; YUPELRI sales up 9%; SVP R&D to depart Feb 2024","bullets":["GAAP net loss from continuing ops $9.0M vs $16.0M prior year; non-GAAP loss $0.7M (improved from $7.1M).","YUPELRI net sales $58.3M (up 9% YoY, 6% QoQ); implied 35% share $20.4M.","Richard Graham, SVP R&D, to depart Feb 29, 2024; part-time from Jan 1; Áine Miller promoted to SVP Development.","Share buybacks $30.8M in Q3; $294.6M total; $30.4M remaining; program expected to complete by year-end 2023.","PIFR-2 study enrollment complete; top-line data Jan 2024. CYPRESS last patient enrollment H2 2024."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-115296","json":"https://secwatch.observer/filing/0001104659-23-115296.json","markdown":"https://secwatch.observer/filing/0001104659-23-115296.md","text":"https://secwatch.observer/filing/0001104659-23-115296.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923115296/0001104659-23-115296-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923115296/tm2330011d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-08T15:21:30.091058+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"f5a9098518ef9242e1bd524638fdbe620d5fabba","claim":"Theravance Biopharma, Inc. reported the third quarter of 2023 results: revenue $15.7 million, net income $9.0 million.","evidence_excerpt":"Total revenue for the third quarter of 2023 was $15.7 million","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923115296/0001104659-23-115296-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter of 2023"},{"label":"Revenue","value":"$15.7 million"},{"label":"Net income","value":"$9.0 million"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"},{"claim_id":"ca6ec16d5d","claim":"Richard Graham departed as Senior Vice President, Research & Development at Theravance Biopharma, Inc..","evidence_excerpt":"In connection with internal changes at Theravance Biopharma, Inc., Richard Graham, Ph.D., Senior Vice President, Research & Development will be leaving the Company on or around February 29, 2024.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1583107/000110465923115296/0001104659-23-115296-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"will be leaving"},{"label":"Role","value":"Senior Vice President, Research & Development"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}